Lazurko C, Clark M, Pulman K, et al. - Researchers focused on hormone maintenance therapy (HMT) efficacy in low-grade serous ovarian cancer (LGSOC) patients when administered following cytoreductive surgery. They explored Medline, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews, and found 14,799 records. This analysis involved four eligible cohort studies with overall 558 patients, of which 127 were treated with HMT. According to findings, it's challenging to treat LGSOC. In one retrospective study, HMT for LGSOC afforded improved progression-free survival, while two others did not demonstrate significant improvements. The generalizability of these results is restricted due to limited data available in the literature. Thus, there is a need for well-designed, prospective, and randomized trials to corroborate the advantage of HMT in patients with this rare subgroup of ovarian cancer.